[go: up one dir, main page]

TNSN04168A1 - Derives de thiazole et d'oxazole qui modulent l'activite de ppar - Google Patents

Derives de thiazole et d'oxazole qui modulent l'activite de ppar

Info

Publication number
TNSN04168A1
TNSN04168A1 TNP2004000168A TNSN04168A TNSN04168A1 TN SN04168 A1 TNSN04168 A1 TN SN04168A1 TN P2004000168 A TNP2004000168 A TN P2004000168A TN SN04168 A TNSN04168 A TN SN04168A TN SN04168 A1 TNSN04168 A1 TN SN04168A1
Authority
TN
Tunisia
Prior art keywords
thiazole
oxazole derivatives
compounds
ppar activity
present
Prior art date
Application number
TNP2004000168A
Other languages
English (en)
Inventor
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Xue-Min Cheng
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of TNSN04168A1 publication Critical patent/TNSN04168A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention fait connaitre des composés qui modifient l'activité de PPAR. La présente invention fait connaître également des sels pharmaceutiquement acceptables les composés; des compositions pharmaceutiquement acceptables comprenant les composés ou leurs ou leurs sels; et des méthodes pour leur utilisation comme agents thérapeutiques a des fins de traitement ou de prévention de l'hyperlipidémie et de l'hypercholestérolémie chez un mammifère. La présente invention fait connaître également des procédés pour la préparation des composés décrits.
TNP2004000168A 2002-03-07 2004-09-03 Derives de thiazole et d'oxazole qui modulent l'activite de ppar TNSN04168A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07
PCT/IB2003/000708 WO2003074050A1 (fr) 2002-03-07 2003-02-24 Derives de thiazole et d'oxazole qui modulent l'activite de ppar

Publications (1)

Publication Number Publication Date
TNSN04168A1 true TNSN04168A1 (fr) 2007-03-12

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000168A TNSN04168A1 (fr) 2002-03-07 2004-09-03 Derives de thiazole et d'oxazole qui modulent l'activite de ppar

Country Status (29)

Country Link
US (1) US20030207924A1 (fr)
EP (1) EP1482935B1 (fr)
JP (1) JP2005528348A (fr)
KR (1) KR20040091693A (fr)
AP (1) AP2004003124A0 (fr)
AR (1) AR038881A1 (fr)
AT (1) ATE405260T1 (fr)
AU (1) AU2003206059A1 (fr)
BR (1) BR0308277A (fr)
CA (1) CA2478520A1 (fr)
CO (1) CO5601012A2 (fr)
DE (1) DE60323060D1 (fr)
EA (1) EA200400943A1 (fr)
EC (1) ECSP045285A (fr)
ES (1) ES2310650T3 (fr)
HN (1) HN2003000090A (fr)
IS (1) IS7377A (fr)
MA (1) MA27181A1 (fr)
MX (1) MXPA04007564A (fr)
NO (1) NO20044242L (fr)
OA (1) OA12780A (fr)
PA (1) PA8567801A1 (fr)
PE (1) PE20030989A1 (fr)
PL (1) PL372969A1 (fr)
TN (1) TNSN04168A1 (fr)
TW (1) TW200305403A (fr)
UY (1) UY27695A1 (fr)
WO (1) WO2003074050A1 (fr)
ZA (1) ZA200406068B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
ATE537825T1 (de) * 2003-05-19 2012-01-15 Irm Llc Immunosuppressive verbindungen und zusammensetzungen
KR20070004769A (ko) * 2004-02-27 2007-01-09 암젠 인코포레이션 대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
EP1745014B1 (fr) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Nouveaux composes, leur preparation et leur utilisation
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2008500358A (ja) * 2004-05-25 2008-01-10 メタボレックス インコーポレーティッド Ｐｐａｒのモジュレーターとしての、二環式の置換されたトリアゾール、およびこれらの調製方法
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
BRPI0606232A2 (pt) * 2005-02-25 2009-06-09 Kang Heonjoong derivados de tiazole como os ligantes delta ppar e seus processos de produção
US7982050B2 (en) * 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
CA2613365C (fr) 2005-06-30 2013-08-13 Novo-Nordisk A/S Acides phenoxyacetiques en tant qu'activateurs de rapp-delta
US8153694B2 (en) * 2005-07-29 2012-04-10 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
WO2008030520A1 (fr) 2006-09-07 2008-03-13 Amgen Inc. Modulateurs hétérocycliques du récepteur couplé à la protéine g (gpr40)
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
WO2008130514A1 (fr) 2007-04-16 2008-10-30 Amgen Inc. Modulateurs de gpr40 des acides biphényle phénoxy, thiophényle et aminophénylpropanoïque substitués
BRPI0818253A2 (pt) 2007-10-10 2015-04-07 Amgen Inc Moduladores de gpr40 bifenil substituídos
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
AU2008345573B2 (en) 2007-12-20 2013-12-19 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2260017A1 (fr) 2008-03-06 2010-12-15 Amgen, Inc Dérivés d'acide carboxylique conformationnellement dépendants, utiles dans le traitement de troubles du métabolisme
ES2450567T3 (es) 2008-10-15 2014-03-25 Amgen, Inc Moduladores de GPR40 espirocíclicos
US20120316346A1 (en) * 2010-02-25 2012-12-13 Snu R & Db Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
EP3043789B1 (fr) 2013-09-09 2020-07-08 vTv Therapeutics LLC Utilisation des agonistes de ppar-delta pour le traitement de l'atrophie musculaire
WO2023147309A1 (fr) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Utilisation d'agonistes ppar-delta dans le traitement d'une maladie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
PL331861A1 (en) * 1996-08-19 1999-08-16 Japan Tobacco Inc Derivatives of propionic acid and their application
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US7091225B2 (en) * 2000-12-20 2006-08-15 Smithkline Beecham Corporation Substituted oxazoles and thiazoles as hPPAR alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
HRP20031002A2 (en) * 2001-06-07 2004-06-30 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)

Also Published As

Publication number Publication date
ECSP045285A (es) 2004-10-26
PE20030989A1 (es) 2003-11-29
AU2003206059A1 (en) 2003-09-16
IS7377A (is) 2004-07-29
ES2310650T3 (es) 2009-01-16
PA8567801A1 (es) 2003-11-12
KR20040091693A (ko) 2004-10-28
EP1482935B1 (fr) 2008-08-20
AP2004003124A0 (en) 2004-09-30
CA2478520A1 (fr) 2003-09-12
HN2003000090A (es) 2004-05-05
DE60323060D1 (de) 2008-10-02
US20030207924A1 (en) 2003-11-06
AR038881A1 (es) 2005-02-02
ZA200406068B (en) 2005-09-06
ATE405260T1 (de) 2008-09-15
EA200400943A1 (ru) 2005-02-24
UY27695A1 (es) 2003-10-31
OA12780A (en) 2006-07-07
TW200305403A (en) 2003-11-01
CO5601012A2 (es) 2006-01-31
JP2005528348A (ja) 2005-09-22
WO2003074050A1 (fr) 2003-09-12
NO20044242L (no) 2004-10-06
PL372969A1 (en) 2005-08-08
MXPA04007564A (es) 2004-11-10
BR0308277A (pt) 2004-12-28
EP1482935A1 (fr) 2004-12-08
MA27181A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
TNSN04168A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
TNSN04167A1 (fr) Derives de thiazole et d'oxazole qui modulent l'activite de ppar
MA27189A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2001090104A3 (fr) Derives de 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
TNSN98112A1 (fr) Composes dipeptidiques
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MA26718A1 (fr) Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2752A1 (fr) Composés et compositions pharmaceutiques pour le traitement du paludisme.
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
TNSN98185A1 (fr) Derives d'isoquinoleine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
MA26725A1 (fr) Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
NO20000771L (no) Anvendelse av fankinon for behandling av Alzheimers sykdom
MX9701116A (es) Profarmacos de 5-(2-[4-(1,2-benzoisotiazol-3-il)-1-piperazinil]etil)-6-clor o-1,3-dihidro-2h-indol-2-ona.